Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"

• Conditions: Stage III Non-small Cell Lung Cancer

• Registration Number: NCT05157503
• Lead Sponsor: Autonomous Non-Profit Organization National Society of Onco-Pulmonologists

Brief Summary

In connection with the transition to the 8th version of the classification of lung cancer according to the TNM system, there are currently no precise epidemiological data on stage III NSCLC, clinical characteristics of patients in this group, approaches to therapy and treatment results in the Russian Federation. The published statistics only provide information on the overall incidence of stage III lung, trachea and bronchial cancer, which is about 40%. This observational study will make it possible to characterize the Russian population of stage III non-small cell lung cancer patients, approaches to choosing a treatment option for stage III NSCLC and the outcomes of this treatment in real clinical practice.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-10
• Study First Submitted: 2020-09-21
• Status Verified: 2021-12
• Study First Submitted QC: 2021-12-01
• Last Update Submitted: 2021-12-01
• Study First Posted: 2021-12-15
• Last Update Posted: 2021-12-15
• Primary Completion: 2023-01-15
• Study Completion: 2023-03-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• stage III non-small cell lung cancer

Exclusion Criteria

• the rest of the disease stage

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Examine clinical and morphological groups	10/01/2023	* gender ratio (husband, wife); * smoking status (smoker, non-smoker, past smoker); * proportional distribution: squamous cell, adenocarcinoma, dimorphic cancer, others); * how many patients with mediastinal lymph node involvement: (N0, N1, N2, N3); * detection frequency: PDL (PDL \<1, PDL\> 1, PDL \<49, PDL\> 50), EGFR (EGFR + (19.24 exon) EGFR-), (ALK +, ALK -), (ROS-1 +, ROS-1 -) Get information about regional algorithms; * Variants of treatment tactics: Percentage: a. Surgery; v. Chemotherapy; -Diagnostic algorithm: a. Morphological verification frequency b. The frequency of confirmation of metastatic lesions within the thoracic lymph nodes c. F

Secondary Outcome Measures

Name	Time	Method
Diagnostic algorithm:	10/01/2023	v. from a variant of molecular genetic disorders; * PDL \<1; * PDL\> 1; * PDL \<49; * PDL\> 50; * EGFR +
Explore clinical approaches	10/01/2023	* Percentage of treatment options depending on: a. histological type; * squamous; * adenocarcinoma; * dimorphic; * 3 A st; * 3B st
Percentage of treatment options	10/01/2023	from functional status; * ECOG 1; 1. only surgical treatment; 2. surgical + drug treatment; 3. surgical + drug treatment + radiation therapy; 4. drug treatment; 5. drug treatment + radiation therapy; 6. radiation therapy; * ECOG 2; 1. only surgical treatment; 2. surgical + drug treatment; 3. surgical + drug treatment + radiation therapy; 4. drug treatment; 5. drug treatment + radiation therapy; 6. radiation therapy; * ECOG 3; 1. only surgical treatment; 2. surgical + drug treatment; 3. surgical + drug treatment + radiation therapy; 4. drug treatment; 5. drug treatment + radiation therapy; 6. radiation therapy

Trial Locations

Locations (1)

National Medical Research Center of Oncology. N. N. Blokhin; 🇷🇺 Moscow, Russian Federation